Abstract:Background Remdesivir (RDV), a nucleotide analog prodrug that targets the viral RNA-dependent RNA polymerase Nsp12, is approved to treat COVID-19 in hospitalized and nonhospitalized patients. Obeldesivir (ODV), an oral mono-5’-isobutyryl ester prodrug that is metabolized into the same active triphosphate as RDV, is being evaluated in Phase 3 clinical trials. The antiviral activity of RDV and ODV against previous Omicron subvariants (BA.1 to BQ.1.1) was maintained with respect to the ancestral WA1 strain. We assessed RDV and ODV antiviral activity against recent Omicron subvariants BF.7, BQ.1, XBB.1.5, CH.1.1, and XBF using clinical isolates and/or site-directed mutants (SDMs). Methods The prevalence of Nsp12 substitutions in Omicron subvariants was evaluated by analysis of Global Initiative on Sharing Avian Influenza Data (GISAID) EpiCoV database sequences. Structural analysis of identified substitutions was conducted on a prior cryo-electron microscopy-based model of the replication-transcription complex. Antiviral activity of RDV and ODV against subvariant clinical isolates was assessed by nucleoprotein ELISA in A549-hACE2-TMPRSS2 cells and by SDMs in the replicon system Results Genomic analysis of > 2 million Omicron subvariant sequences revealed unique substitutions in Nsp12 vs WA1. No new defining substitutions in Nsp12 were found compared with earlier Omicron variants. The defining substitutions (≥ 75% of sequences) included P323L (all), Y273H (BQ.1), and G671S (XBB.1.5, CH.1.1, XBF). Less prevalent substitutions were observed with frequencies from 1-3.5%: L247F, T248I, V257F, N507I, A529V, F694Y; none had direct interaction with the incoming RDV nucleotide triphosphate or the viral RNA, except N507I. Phenotyping of individual substitutions using SDMs showed no loss of RDV or ODV susceptibility (< 1.2-fold change in EC50 vs WA1). Evaluation of CH.1.1 and XBF by introducing variant-defining mutations into the replicon showed no change in in vitro susceptibility (< 1.8-fold change). Phenotyping of clinical isolates of BF.7, BQ.1, XBB.1.5, and CH.1.1 indicated no loss of RDV or ODV in vitro antiviral activity (< 1.3-fold change). Conclusion RDV and ODV retained potent in vitro antiviral activity against all tested Omicron subvariants with potencies comparable to WA1. Disclosures Lauren Rodriguez, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Jiani Li, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Dong Han, MS, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Ross Martin, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Jasmine Moshiri, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Nadine Peinovich, MPH, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds John P. Bilello, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Jason K. Perry, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds Charlotte Hedskog, PhD, Gilead Sciences, Inc.: Employee|Gilead Sciences, Inc.: Stocks/Bonds

Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants

Structural basis for Nirmatrelvir in vitro efficacy against SARS-CoV-2 variants

Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals

545. Remdesivir and Obeldesivir Retain Potent Activity Against SARS-CoV-2 Omicron Variants

Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants

Molecular Mechanisms of SARS-CoV-2 Resistance to Nirmatrelvir

The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses

Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of Concern

Advances and Challenges in Using Nirmatrelvir and Its Derivatives Against SARS-CoV-2 Infection.

Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models

A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2

In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance

The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19.

SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron Variant of SARS-CoV-2

Discovery of C-Linked Nucleoside Analogues with Antiviral Activity against SARS-CoV-2

A New Generation Mpro Inhibitor with Potent Activity Against SARS-CoV-2 Omicron Variants

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants

The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants

Computational Insights into SARS-CoV-2 Main Protease Mutations and Nirmatrelvir Efficacy: The Effects of P132H and P132H-A173V

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1